Last updated: 4 July 2019 at 2:04am EST

John Stuart Patton Net Worth




The estimated Net Worth of John Stuart Patton is at least $2.36 Million dollars as of 19 August 2014. John Patton owns over 75,000 units of Nektar Therapeutics stock worth over $318,595 and over the last 21 years John sold NKTR stock worth over $2,041,090.

John Patton NKTR stock SEC Form 4 insiders trading

John has made over 15 trades of the Nektar Therapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently John exercised 75,000 units of NKTR stock worth $153,750 on 19 August 2014.

The largest trade John's ever made was exercising 100,000 units of Nektar Therapeutics stock on 13 September 2013 worth over $39,000. On average, John trades about 8,072 units every 55 days since 2004. As of 19 August 2014 John still owns at least 254,876 units of Nektar Therapeutics stock.

You can see the complete history of John Patton stock trades at the bottom of the page.



What's John Patton's mailing address?

John's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE 17, SAN DIEGO, CA, 92121.

Insiders trading at Nektar Therapeutics

Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.



What does Nektar Therapeutics do?

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.



What does Nektar Therapeutics's logo look like?

Nektar Therapeutics logo

Complete history of John Patton stock trades at Halozyme Therapeutics and Nektar Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Aug 2014 John Stuart Patton
Director
Option 75,000 $2.05 $153,750
19 Aug 2014
254,876
13 Sep 2013 John Stuart Patton
Director
Option 100,000 $0.39 $39,000
13 Sep 2013
230,000
16 Oct 2007 John Stuart Patton
Director
Sale 15,000 $9.04 $135,600
16 Oct 2007
15,000
9 Oct 2007 John Stuart Patton
Director
Sale 15,000 $8.69 $130,350
9 Oct 2007
30,000
2 Oct 2007 John Stuart Patton
Director
Sale 15,000 $8.90 $133,500
2 Oct 2007
45,000
25 Sep 2007 John Stuart Patton
Director
Sale 15,000 $8.94 $134,100
25 Sep 2007
60,000
18 Sep 2007 John Stuart Patton
Director
Sale 17,471 $8.93 $156,016
18 Sep 2007
75,000
10 Jul 2007 John Stuart Patton
Director
Sale 20,000 $9.78 $195,600
10 Jul 2007
92,471
26 Jun 2007 John Stuart Patton
Director
Sale 8,200 $8.98 $73,636
26 Jun 2007
112,471
26 Jun 2007 John Stuart Patton
Director
Sale 11,800 $8.66 $102,188
26 Jun 2007
120,671
19 Jun 2007 John Stuart Patton
Director
Sale 20,000 $10.25 $205,000
19 Jun 2007
132,471
12 Jun 2007 John Stuart Patton
Director
Sale 20,000 $10.05 $201,000
12 Jun 2007
152,471
29 May 2007 John Stuart Patton
Director
Sale 20,000 $10.27 $205,400
29 May 2007
172,471
23 May 2007 John Stuart Patton
Director
Sale 15,000 $10.50 $157,500
23 May 2007
192,471
22 May 2007 John Stuart Patton
Director
Sale 20,000 $10.56 $211,200
22 May 2007
207,471


Nektar Therapeutics executives and stock owners

Nektar Therapeutics executives and other stock owners filed with the SEC include: